{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-000830","form_type":"8-K","ticker":"VERA","cik":"0001831828","company_name":"Vera Therapeutics, Inc.","filed_at":"2023-01-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.912583+00:00","generated_at":"2026-06-20T21:00:58.851285+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Vera Therapeutics reports positive Phase 2b ORIGIN topline: primary endpoint met in IgA nephropathy","bullets":["UPCR reduced 31% with pooled 75/150 mg dose (p=0.037 vs placebo) and 33% with 150 mg (p=0.047) at week 24.","eGFR stabilized in atacicept arm through week 24; Gd-IgA1 reduced robustly from baseline.","Safety well-tolerated: 1% discontinuation due to AEs, serious TEAEs 2% atacicept vs 9% placebo.","Company plans to advance atacicept into pivotal Phase 3 development in H1 2023 subject to FDA discussions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-000830","json":"https://secwatch.observer/filing/0001193125-23-000830.json","markdown":"https://secwatch.observer/filing/0001193125-23-000830.md","text":"https://secwatch.observer/filing/0001193125-23-000830.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831828/000119312523000830/0001193125-23-000830-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831828/000119312523000830/d445567d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T21:00:58.851285+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}